Comparison of the enamel solubility reduction from Various prescription and OTC fluoride toothpastes and gels.
The purpose of this in vitro study was to determine if a novel 970 ppm F ion SnF2OTC gel (Enamelon Preventive Treatment Gel) and a 1150 ppm F- ion SnF2OTC Enamelon Toothpaste, each delivering amorphous calcium phosphate (ACP), can significantly reduce the effect of an acid challenge to enamel as compared to two prescription (Rx) strength 5000 ppm F- ion (NaF) dentifrices containing tri-calcium phosphate (TCP), and an Rx 900 ppm F- ion (NaF) paste with casein phosphopeptide-amorphous calcium phosphate (CPP-ACP). The effect will be determined by measuring the resistance of enamel specimens to an acid challenge before and after treatment with the test dentifrices. The procedure used in this study was the FDA Test Method #33 for the determination of the effect of different test dentifrices on enamel solubility reduction. Twelve sets of three extracted human teeth were unprotected and etched prior to treatment with 0.1 M lactic acid buffer solution. The amount of phosphate dissolved from the teeth was quantified via measuring the phosphate in the retained lactate buffer solution with phosphorous analysis (pre-treatment phosphorous levels). The teeth sets were then exposed to the following treatments (diluted 1:3 parts in preheated [37 degrees C] distilled water): 5000 ppm F- ion, sodium fluoride (NaF) Rx dentifrice containing TCP; 5000 ppm F- ion, NaF Rx dentifrice; 900 ppm F- ion, NaF Rx paste with CPP-ACP; 1150 ppm F- ion, stannous fluoride (SnF2) OTC toothpaste delivering ACP Enamelon Toothpaste; and 970 ppm F- ion, SnF2 OTC gel delivering ACP (Enamelon Preventive Treatment Gel). The teeth sets were rinsed with distilled water and then exposed to 0.1 M buffered lactic acid solution. The amount of phosphate in the lactic acid buffer was determined for a second time (post-treatment phosphorous levels). The percent of enamel solubility reduction was then computed as the difference between the amount of phosphorous in the pre- and post-treatment lactic acid solutions divided by the amount of phosphorous in the pre-treatment solution, and multiplied by 100. The percent reduction in enamel solubility recorded in this study was as follows: 60.14 ± 0.79 for the Enamelon Toothpaste; 56.91 ± 1.05 for the Enamelon Preventive Treatment Gel; 18.78 ± 3.20 for the 5000 ppm F- ion, NaF prescription dentifrice "A' with TCP; 6.84 ± 1.20 for the 900 ppm F- ion, NaF paste with CPP-ACP; 5.82 ± 3.10 for the 5000 ppm F- ion, NaF prescription dentifrice "B" with TCP; and -5.45 ± 1.86 for the negative control. The differences between all the products tested were statistically significant (p < 0.05), except for the Enamelon products that were not statistically different. The 900 ppm F- ion, NaF paste with CPP-ACP and the 5000 ppm F- ion, NaF toothpaste results were also not statistically different. The Enamelon products (970 ppm and 1150 ppm F- ion, SnF2 OTC dentifrices) delivering ACP were statistically significantly more effective in reducing enamel solubility than two Rx strength 5000 ppm F- ion NaF toothpastes containing TCP and the Rx 900 ppm F- ion NaF paste containing CPP-ACP.